A major Aussie university and ASX-listed company will deploy psychedelic drugs to treat binge-eating in a world-first clinical trial. Experimental healthcare company Tryptamine Therapeutics announced ...
Tryptamine Therapeutics has reached a milestone in development of its novel IV-infused psilocin formulation TRP-8803, with the drug meeting all phase 1b study objectives. Tryptamine Therapeutics ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback